ALLMedicine™ Hypogammaglobulinemia Center
Research & Reviews 594 results
https://doi.org/10.1007/s10875-022-01303-8
Journal of Clinical Immunology; Huisman EJ, Brooimans AR et. al.
Jun 29th, 2022 - Disorders of the long arm of chromosome 11 (11q) are rare and involve various chromosomal regions. Patients with 11q disorders, including Jacobsen syndrome, often present with a susceptibility for bacterial and prolonged viral and fungal infection...
https://doi.org/10.1007/s00467-022-05652-9 10.1007/s00467-017-3718-0 10.1016/S0140-6736(14)60541-9 10.1007/s00467-020-04519-1 10.1016/j.ijid.2010.03.025 10.1080/08830185.2017.1346092 10.1001/jamanetworkopen.2018.4169 10.3390/cancers7010305 10.1016/j.jpeds.2012.11.038 10.1007/s00467-021-05304-4 10.1007/s00467-019-04398-1 10.1007/s10157-020-01858-z 10.12998/wjcc.v7.i9.1021 10.5414/CN108835 10.1186/s12969-019-0365-y 10.1007/s12185-010-0528-6 10.1016/j.autrev.2019.03.010 10.1016/j.clml.2012.11.011 10.1016/S1081-1206(10)60665-5 10.1007/s00467-012-2286-6 10.1093/rheumatology/keq368 10.1093/ckj/sfx014 10.1186/1471-2474-15-178 10.1002/art.23059 10.1093/rheumatology/key306 10.3899/jrheum.140863 10.1016/j.jiph.2018.09.006 10.1111/j.1440-1797.2012.01650.x 10.1056/NEJMoa1405870 10.1016/j.vaccine.2020.11.004 10.1016/j.semarthrit.2008.05.002 10.1002/art.23171 10.1016/j.jaut.2014.11.004 10.1001/jamanetworkopen.2020.36321
Pediatric Nephrology (Berlin, Germany); Inoki Y, Nishi K et. al.
Jun 25th, 2022 - Hypogammaglobulinemia is a major adverse effect from rituximab. However, the association between rituximab-induced hypogammaglobulinemia and infection frequency is unknown. Patients who received rituximab for complicated nephrotic syndrome between...
https://doi.org/10.1016/j.clim.2022.109067
Clinical Immunology (Orlando, Fla.); Al-Tamemi S, Alhinai Z et. al.
Jun 25th, 2022 - Severe combined immunodeficiency (SCID) is characterized by severe, early-onset infection in infants. B-cell lymphoma/leukemia (BCL) 10 defects causing SCID have been reported previously in two patients. A seven-month-old female infant was admitte...
https://clinicaltrials.gov/ct2/show/NCT00967785
Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT02579967
Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...
Drugs 6 results see all →
Clinicaltrials.gov 41 results
https://clinicaltrials.gov/ct2/show/NCT02579967
Jun 24th, 2022 - Background: Primary immunodeficiency diseases (PIDs) are conditions associated with major quantitative or qualitative immunologic abnormalities that are, in most cases, due to defects in cells of hematopoietic origin Participants with PID can have...
https://clinicaltrials.gov/ct2/show/NCT00032513
Jun 24th, 2022 - Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in...
https://clinicaltrials.gov/ct2/show/NCT04339777
Jun 24th, 2022 - Background: With the availability of whole exome sequencing (WES) and whole genome sequencing (WGS) for patients with suspected primary immune deficiency or Primary Immune Regulatory Disorder (PIRD), the number of recognized PID s and PIRD s has i...
https://clinicaltrials.gov/ct2/show/NCT00967785
Jun 24th, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...
https://clinicaltrials.gov/ct2/show/NCT05357781
May 3rd, 2022 - Multiple sclerosis (MS) is the most common cause of mental and physical disability in young adults affecting approximately 10'000-15'000 persons in Switzerland (incidence 16/100000; prevalence 190/100000). MS-fatigue affects at least 75% of the MS...
News 51 results
https://www.mdedge.com/dermatology/article/252371/autoimmune-diseases/interstitial-granulomatous-dermatitis-adverse
Katherine G. Beuerlein, BS, Elise D. Martin, MD et. al.
Mar 3rd, 2022 - The number of monoclonal antibodies developed for therapeutic use has rapidly expanded over the last decade due to their generally favorable adverse effect (AE) profiles and efficacy. 1 Tumor necrosis factor α inhibitors and general integrin antago.
https://www.medpagetoday.com/hematologyoncology/myeloma/97437
Mar 1st, 2022 - The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced. Ciltacabtagene autoleucel, a B-...
https://www.onclive.com/view/zanubrutinib-sbla-for-waldenstr-m-macroglobulinemia-accepted-in-china
Jan 21st, 2022 - The China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) for zanubrutinib (Brukinsa) as a treatment for adult patients with Waldenström macroglobulinemia.1 The application is supported by...
https://www.onclive.com/view/fda-approval-sought-for-teclistamab-for-relapsed-refractory-multiple-myeloma
Dec 29th, 2021 - A biologics license application seeking the approval of the off-the-shelf, T-cell redirecting bispecific antibody, teclistamab (JNJ-64007957), for use in patients with relapsed or refractory multiple myeloma has been submitted to the FDA.1 The ap...
https://www.onclive.com/view/kahl-weighs-the-complexities-of-treatment-selection-in-indolent-lymphoma
Oct 6th, 2021 - Brad S. Kahl, MD Optimizing treatment for patients with indolent non-Hodgkin lymphoma (iNHL) has become a challenge as the frontline and recurrent treatment settings continue to evolve, said Brad S. Kahl, MD. "The management of [recurrent] indol...